Healthcare providers who prescribe opioid analgesics have a responsibility to help ensure the safe and effective use of opioid analgesics. The FDA REMS-compliant accredited continuing education (CE) programs will focus on the safe prescribing of opioid analgesics.
The FDA REMS-compliant accredited CE will: (a) be delivered by accredited CE providers; (b) cover all elements of the updated Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain ("FDA Blueprint"); (c) include a knowledge assessment; and (d) be subject to independent audit of content and compliance with applicable accrediting standards.
The FDA has developed core messages to be communicated to providers in the Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain ("FDA Blueprint") , which will be used by accredited CE Providers to develop the REMS-compliant accredited CE programs.
These core messages include:
Listing of Accredited CE REMS-Compliant Activities Supported by RPCUPDATED
Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain ("FDA Blueprint") for 2021 - 2023 Grantees
Opioid Analgesic REMS Education Blueprint for Health Care Providers Involved in the Treatment and Monitoring of Patients with Pain ("FDA Blueprint") NEW for 2024 Grantees
If you are an accredited CE Provider, click here for more information.